Showing posts with label gives. Show all posts
Showing posts with label gives. Show all posts

Friday, July 12, 2013

Mike Bloomberg Gives Debunked Excuse For Opposing Paid Sick Leave Legislation

New York City Mayor Mike Bloomberg (I) has promised to veto his city council’s final version of paid sick leave legislation, and is using flawed reasoning to defend his decision to do so.

Bloomberg claims that the legislation, which would provide five days of paid leave for employees of companies bigger than 15 people, would “hurt small businesses and stifle job creation… Supporters claim it will only take effect if the economy is healthy, but there is never a good time to make New York City less competitive. The bill is short-sighted economic policy that will take our city in the wrong direction, and I will veto it.”

It’s a good thing that the council has enough votes to override Bloomberg’s veto, because his reason for opposing the law doesn’t add up. Several studies have demonstrated that paid sick leave has no effect on job creation. In fact, a survey by Public Citizen found that when San Francisco enacted paid sick day legislation (a bill that required far more businesses to comply), it saw a jump in business expansion and employment growth (PDF):

But after implementation of the paid sick-leave law, San Francisco experienced an increase in employment. A study by the Drum Major Institute found that employment in San Francisco increased 3.5 percent between the start of 2006 and the start of 2010. In San Francisco’s five closest neighboring counties, employment fell 3.4 percent during the same period. The same study found that despite predictions to the contrary, the number businesses in San Francisco grew by 1.64 percent between 2006 and 2008 while falling by 0.61 percent in neighboring counties. San Francisco also experienced growth within both large and small businesses, and within the retail and food service industry during this period. (These industries expected to be affected most by the ordinance.)

The impact on businesses themselves was minor. A majority reported that understanding and implementing the ordinance was either “not difficult” or “not too difficult.” Additionally, while only 14 percent of businesses reported a negative impact on profits, more than 70 percent reported that the law had either no impact or a positive impact on their profitability. Productivity, and thus profitability, suffers when workers are forced to come to work when they are sick. One study on the impact of illness on productivity estimates that businesses lose twice as much money to workers who show up at work while sick than when workers stay home due to an illness.

Another study of Connecticut, done by the Center for American Progress, found much the same thing, noting that “full use of this leave would cost an employer only 0.4 percent of their sales revenue on average. Without paid sick days, employees come to work unhealthy, costing employers $160 billion per year due to lower productivity levels.”

There are myriad benefits to paid sick leave outside of workforce productivity; it helps families, is good for morale, and helps people recover from illness. Business efficiency can’t be the only end goal. But if Bloomberg is inspired by business interests alone, then he should still feel compelled to support the law. Three million Americans workers missed a day at their job because of illness in the month of February alone. It’s likely many did so without pay; 40 percent of private sector workers and 80 percent of low-income workers have no paid sick leave, and are likely to pick coming to work sick over missing a day of wages. That means they’re spreading illness to customers, getting more people sick, and being less efficient overall.


View the original article here

Friday, June 21, 2013

Sanofi says MS Lemtrada drug gives long-term benefit

PARIS, March 21 (Reuters) - The effects of Sanofi's

experimental multiple sclerosis drug Lemtrada continue to benefit the majority of patients long after they have completed their treatment, the French drugmaker said on Thursday.

In an extension trial sponsored by the company that followed up patients who had taken part in two late-stage studies, more than half did not experience any relapses in the first year after completing a two-course treatment with Lemtrada.

Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision. It affects 2.5 million people worldwide and has no cure.

Lemtrada, which is given via an intravenous drip for five days and then for three days a year later, has the potential to re-programme the immune system and could potentially change the long-term progression of the disease.

"When you think about therapies to treat MS you think of therapies that are taken chronically, that when you stop them their effects are gone," Michael Panzara, therapeutic area head for MS and neurological research at Sanofi's rare disease unit Genzyme, told Reuters.

"What you have here is a change in the immune system and a prolonged effect."

The study showed that more than 80 percent of patients did not require a third course of Lemtrada in the first year after treatment, while more than 70 percent of patients showed improved or stable disability after three years.

"These findings are important because they suggest that the benefits of Lemtrada as observed in phase III studies are maintained, even though most patients did not receive further dosing," said Edward Fox, director of the Multiple Sclerosis Clinic of Central Texas, who presented the results at a medical congress in San Diego, California.

Lemtrada is under review by the European Medicines Agency and the U.S. Food and Drug Administration, which are expected to give their feedback by the end of 2013.

In addition to Lemtrada, Sanofi has developed MS pill Aubagio to boost growth after the patent loss on its ageing blockbusters and further its ambition to become a major player in this market.

Aubagio was launched in the U.S. in October, generating sales of 7 million euros ($9 million) in the last quarter of 2012.

The European Medicines Agency is due to give its verdict on the drug by the end of the month.

Shares in Sanofi, which have risen around 8 percent in the last month in the run-up to EMA's decision, closed at 77.32 euros on Thursday.

($1 = 0.7722 euros)

(Reporting by Elena Berton; editing by Keiron Henderson)

((elena.berton@thomsonreuters.com)(+33149495226)(Reuters

Messaging: elena.berton.thomsonreuters.com@reuters.net))

Keywords: SANOFI LEMTRADA/


View the original article here

Sunday, February 17, 2013

Amgen Gives Early Payday to the Bulls

Amgen, which was down slightly when the trades occurred, closed the session up 1.47 percent to $83.29. The stock fell on Jan. 8 after the company had cut its guidance because of a tax credit, but management remained sanguine over the longer term. That could be leading some investors to expect a positive report this afternoon.

Total option volume in the name was almost nine times greater than average in the session.


—By CNBC Contributor David Russell

Additional News: Top Biotech Trades

Additional Views: CBS Bulls Are Poised for Big Gains: Russell

___________________________

Options Trading School:

___________________________
Disclosures:

David Russell is a reporter and writer for OptionMonster. Russell has no positions in AMGN.

___________________________

.Disclaimer


View the original article here

Friday, April 6, 2012

Tech at Night: FCC gives in to Chuck Grassley, Republicans question the rush to privacy regulations

Tech at Night


Am I tired of expressing dissatisfaction with the Obama FCC and other government intrusions? Never!


Al Franken is setting up an unfalsifiable rationale for government action against Verizon and Comcast. Gotta love that, eh?


I’m sure he, the FCC, or both will try to overturn the courts who say bundling is not anticompetitive. I like bundling. It saves me money when I’m buying both things anyway. Then again, I like choices in the marketplace.


Why we want FCC subsidizing tablet makers though, I have no idea.


Chuck Grassley’s threat seems to be working at least, as FCC starts to break down on LightSquared transparency, a necessary step toward being able to confirm the President’s new appointees to the commission.


Sprint continues to try to drum up government action, and also continuing to strain the bounds of credulity. Sprint says there’s a 4G duopoly, conveniently forgetting the fact that Sprint was the first major entry into the 4G market. Sprint just chose the wrong technology (WiMAX, instead of the apparently-winning LTE), the latest in a series of bad business decisions.


PATENT WARS: Even as Apple considers changing its patent strategies against firms like Samsung deploying Android, it turns out Nokia may provoke a whole new patent war over SIM card technology.


I’ve long plead for Mary Bono Mack to ease up on privacy issues, fearing it would lead to bad government action. Fortunately she seems to see those risks as well, and other Republicans like Marsha Blackburn also see the dangers of “a massive expansion of government… that would put some limits on our individual liberties.” Yes, yes, yes, exactly. That’s why I say we need to get privacy issues back into the realm of common sense self precautions, not government dictates.


This will be the last Tech at Night from California. Also because of my move to Virginia next week, will be no posting Monday or Wednesday as I will be traveling across the country to my new home, so have fun until next week!


View the original article here